Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Tenofovir

Criteria

Inclusion Criteria:

• Positive hepatitis b surface antigen and hepatitis b antibody > 0.5 year;

• Age from 18 to 65 years old;

• Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;

• Positive Hepatitis b virus(HBV);

• Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.

Exclusion Criteria:

• Other active liver diseases;

• Hepatocellular carcinoma or other malignancy;

• Pregnancy or lactation;

• Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.